Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Buy” by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned a consensus recommendation of “Buy” from the eighteen brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, fifteen have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $262.6875.

ASND has been the topic of several analyst reports. Stifel Nicolaus increased their price target on shares of Ascendis Pharma A/S from $254.00 to $256.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Raymond James Financial started coverage on Ascendis Pharma A/S in a research note on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 price target on the stock. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $325.00 price objective on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $205.83 on Monday. The stock has a market cap of $12.76 billion, a PE ratio of -46.36, a P/E/G ratio of 1.09 and a beta of 0.46. The firm has a 50-day moving average of $208.70 and a 200-day moving average of $198.15. Ascendis Pharma A/S has a 52-week low of $118.03 and a 52-week high of $229.94.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. As a group, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Braun Stacey Associates Inc. bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $18,678,000. Calamos Advisors LLC acquired a new stake in Ascendis Pharma A/S in the third quarter worth $1,282,000. Allianz Asset Management GmbH increased its stake in Ascendis Pharma A/S by 144.7% in the second quarter. Allianz Asset Management GmbH now owns 9,300 shares of the biotechnology company’s stock valued at $1,605,000 after purchasing an additional 5,500 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in shares of Ascendis Pharma A/S by 630.5% during the second quarter. Kennedy Capital Management LLC now owns 18,628 shares of the biotechnology company’s stock valued at $3,215,000 after purchasing an additional 16,078 shares during the period. Finally, Marshall Wace LLP raised its holdings in shares of Ascendis Pharma A/S by 425.5% during the second quarter. Marshall Wace LLP now owns 117,162 shares of the biotechnology company’s stock valued at $20,222,000 after purchasing an additional 94,868 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.